(2-乙酰氨基-噻唑-4-基)-乙酸 | 202408-30-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: (2-乙酰氨基-噻唑-4-基)-乙酸
• 英文名称: 2-(2-acetamidothiazol-4-yl)acetic acid
• 英文别名: 2-(acetylaminothiazol-4-yl)acetic acid；2-(2-acetylaminothiazol-4-yl)acetic acid；(2-Acetylamino-thiazol-4-yl)-acetic acid；2-(2-acetamido-1,3-thiazol-4-yl)acetic acid
• CAS: 202408-30-8
• 化学式: C₇H₈N₂O₃S
• mdl: MFCD01325999
• 分子量: 200.218
• InChiKey: KCOJFJKNUZUGHX-UHFFFAOYSA-N

物化性质

• 密度：
  1.509±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  108
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2934100090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P330,P363,P501
• 危险性描述：
  H302,H312,H332

反应信息

• 作为反应物：
  描述：

  (2-乙酰氨基-噻唑-4-基)-乙酸 在 sodium hydroxide 、 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.5h， 生成
  参考文献：
  名称：

  Synthesis of a novel thiazole based dipeptide chemosensor for Cu(II) in water

  摘要：

  A thiazole-based novel dipeptide module has been synthesized, which exhibited selective Cu(II) recognition in water in the presence of other competing divalent transition metal ions at micromolar concentrations. This is the first example of an entirely synthetic peptide based chemosensor for Cu(II). (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(00)01853-0
• 作为产物：
  描述：

  2-氨基-4-噻唑乙酸乙酯 在 sodium hydroxide 作用下， 以 溶剂黄146 为溶剂， 反应 7.5h， 生成 (2-乙酰氨基-噻唑-4-基)-乙酸
  参考文献：
  名称：

  Synthesis of a novel thiazole based dipeptide chemosensor for Cu(II) in water

  摘要：

  A thiazole-based novel dipeptide module has been synthesized, which exhibited selective Cu(II) recognition in water in the presence of other competing divalent transition metal ions at micromolar concentrations. This is the first example of an entirely synthetic peptide based chemosensor for Cu(II). (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(00)01853-0

文献信息

• Synthesis and Evaluation of <i>N</i>-Phenyl-(2-aminothiazol-4-yl)acetamides with Phenoxypropanolamine Moiety as Selective β3-Adrenergic Receptor Agonists
  作者：Tatsuya Maruyama、Kenichi Onda、Takayuki Suzuki、Masahiko Hayakawa、Takumi Takahashi、Tetsuo Matsui、Toshiyuki Takasu、Itsuro Nagase、Mitsuaki Ohta

  DOI：10.1248/cpb.60.647

  日期：——

  In the search for potent and selective human β3-adrenergic receptor (AR) agonists as potential drugs for use in treating obesity and non-insulin dependent (type 2) diabetes, a series of N-phenyl-(2-aminothiazol-4-yl)acetamides with phenoxypropanolamine moiety were prepared and their biological activities against human β3-, β2-, and β1-ARs were evaluated. Among these compounds, N-phenyl-(2-phenylam

  在寻找有效的和选择性的人β3-肾上腺素能受体（AR）激动剂作为治疗肥胖症和非胰岛素依赖型（2型）糖尿病的潜在药物时，一系列N-苯基-（2-氨基噻唑-4-基制备了具有苯氧基丙醇胺部分的乙酰胺，并评估了其对人β3-，β2-和β1-ARs的生物学活性。在这些化合物中，N-苯基-（2-苯基氨基噻唑-4-基）乙酰胺（4 g），N-苯基-（2-苄基氨基噻唑-4-基）乙酰胺（4j）和N-苯基-[2-（ 3-甲氧基苯基）氨基噻唑-4-基]乙酰胺（6g）衍生物显示出对β3-AR的强效激动活性，并具有对β1-和β2-AR的功能选择性。另外，这些化合物在糖尿病的啮齿动物模型中表现出显着的降血糖活性。
• Naphthyridine derivatives
  申请人：Yamanouchi Pharmaceutical Co., Ltd.

  公开号：US06740662B1

  公开（公告）日：2004-05-25

  2-Oxo-1,2-dihydro-1,8-naphthyridine derivatives characterized by bearing a specific substituent, —X—R6, at the 3-position and a cyclic substituent, R5, at the 4-position; or salts thereof. The derivatives and the salts are useful as drugs, particularly preventive or therapeutic agents for respiratory diseases related to PDE IV.

  2-氧代-1,2-二氢-1,8-萘啶衍生物，其在3位上带有特定取代基——X—R6，在4位上带有环状取代基R5；或其盐。这些衍生物和盐可用作药物，特别是用于与PDE IV有关的呼吸系统疾病的预防或治疗剂。
• [EN] SUBSTITUTED ACRYLAMIDO-PENICILLANIC ACID DERIVATIVES
  申请人：SMITHKLINE BEECHAM, PLC

  公开号：WO1993004070A1

  公开（公告）日：1993-03-04

  (EN) $g(b)-lactam antibiotics of formula (I) or a salt thereof: wherein X is hydrogen or a group NHR1, wherein R1 is hydrogen or an amino protecting group, and R is an optionally substituted spiro, fused or bridged bicyclic or tricyclic group optionally containing one or more heteroatoms selected from oxygen, nitrogen and sulphur, useful in the treatment of bacterial infections in humans and animals.(FR) Cette invention concerne des bêta-lactamines de formule (I) ou un de leurs sels. Dans cette formule, X représente hydrogène ou un groupe NHR1, dans lequel R1 représente hydrogène ou un groupe protecteur amino, et R représente un groupe bicyclique ou tricyclique spiro, fusionné ou ponté facultativement substitué, contenant facultativement au moins un hétéroatome sélectionné parmi oxygène, azote et soufre. Ces nouveaux composés sont utiles dans le traitement des infections bactériennes chez l'homme et les animaux.

  该发明涉及β-内共生胺类药物，其化学式为(I)或其盐类。在这些化合物中，X代表氢或-NHR₁，其中的R₁代表氢或氨基保护基团，并且R代表一个可选取代的疏 concerted bicyclic或tricyclic环系，可能包含一个或多个选自氧、氮和硫的hetero原子。这些新化合物可用于治疗人类和动物的细菌感染。
• NAPHTHYRIDINE DERIVATIVES
  申请人：Astellas Pharma Inc.

  公开号：EP1225173B1

  公开（公告）日：2005-09-28
• Pyridinylquinazolines Selectively Inhibit Human Methionine Aminopeptidase-1 in Cells
  作者：Feiran Zhang、Shridhar Bhat、Sandra B. Gabelli、Xiaochun Chen、Michelle S. Miller、Benjamin A. Nacev、Yim Ling Cheng、David J. Meyers、Karen Tenney、Joong Sup Shim、Phillip Crews、L. Mario Amzel、Dawei Ma、Jun O. Liu

  DOI：10.1021/jm400227z

  日期：2013.5.23

  Methionine aminopeptidases (MetAPs), which remove the initiator methionine from nascent peptides, are essential in all organisms. While MetAP2 has been demonstrated to be a therapeutic target for inhibiting angiogenesis in mammals, MetAP1 seems to be vital for cell proliferation. Our earlier efforts identified two structural classes of human MetAP1 (HsMetAP1)-selective inhibitors (14), but all of them failed to inhibit cellular HsMetAP1. Using Mn(II) or Zn(II) to activate HsMetAP1, we found that 14 could only effectively inhibit purified HsMetAP1 in the presence of physiologically unachievable concentrations of Co(II). In an effort to seek Co(II)-independent inhibitors, a novel structural class containing a 2-(pyridin-2-yl)quinazoline core has been discovered. Many compounds in this class potently and selectively inhibited HsMetAP1 without Co(II). Subsequently, we demonstrated that 11j, an auxiliary metal-dependent inhibitor, effectively inhibited HsMetAP1 in primary cells. This is the first report that an HsMetAP1-selective inhibitor is effective against its target in cells.